Breaking News

Jubilant HollisterStier Site Approved for Lantheus Products

February 11, 2013

Will manufacture and supply DEFINITY, Cardiolite and Neurolite

The FDA has granted approval of Lantheus Medical Imaging’s sNDA, allowing Jubilant HollisterStier (JHS) to be a new manufacturing site for its ultrasound imaging agent, DEFINITY Vial for (Perflutren Liquid Microsphere) Injectable Suspension.
 
“FDA approval of JHS as a new manufacturer for DEFINITY is a major step forward in providing consistent and reliable supply to our customers,” said Jeff Bailey, Lantheus president and chief executive officer. “Supply chain diversification is a significant priority for the company as we work to ensure long-term product availability to meet market demand. We remain dedicated to providing the highest quality products to our customers and the patients they serve.”
 
DEFINITY is currently manufactured by Ben Venue Laboratories in Bedford, OH. In August 2011, Ben Venue announced plans to exit the contract manufacturing services business, which will take place during the next several years. In February 2012, Lantheus entered into a manufacturing and supply agreement with JHS for DEFINITY, as well as the manufacture and supply of Cardiolite and Neurolite, which are also manufactured by Ben Venue.

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.